RecruitingNot ApplicableNCT07559084

Multi-target TMS for Schizophrenia Negative Symptoms

Development of a Multi-target Transcranial Magnetic Intervention Technique for Negative Symptoms of Schizophrenia


Sponsor

Shanghai Mental Health Center

Enrollment

64 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the left dorsolateral prefrontal cortex (L-DLPFC), left inferior parietal lobule (L-IPL), and right orbitofrontal cortex (R-OFC) for negative symptoms of schizophrenia.


Eligibility

Min Age: 16 YearsMax Age: 45 Years

Inclusion Criteria7

  • Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center;
  • Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment;
  • Male or female aged 16-45 years;
  • Education duration ≥ 9 years;
  • Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit;
  • Participants and their guardians can understand and sign written informed consent;
  • Total score on the PANSS Negative Symptom subscale (PANSS-N) > 15, and at least one item score ≥ 3.

Exclusion Criteria5

  • Current or lifetime psychiatric disorders as determined by SCID-5 assessment;
  • Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions;
  • Alcohol abuse within 30 days prior to the study or alcohol/drug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline;
  • Pregnant or breastfeeding women;
  • Intellectual disability (IQ < 70).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICErepetitive transcranial magnetic stimulation (rTMS)

Repetitive transcranial magnetic stimulation (rTMS) is a recently developed neuromodulation technique.


Locations(1)

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07559084


Related Trials